Focada exclusivamente no desenvolvimento, 
                                        produção e promoção de produtos farmacêuticos especializados


BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33) in accordance with the Brazilian Securities and Exchange Commission (“CVM”) Rule No. 358, dated as of January 3rd, 2002, and following the material fact disclosed by the Company on August 14th, 2020, in the context of the unified tender offer launched by 11718991 Canada Inc. (the “Offeror”), a wholly owned subsidiary of Knight Therapeutics Inc., for the acquisition of BDRs representing shares of the Company, aiming at (i) fulfilling the Offeror’s statutory obligation to conduct a public offer for the acquisition of the outstanding BDRs following the transfer of control (“Tag Along Tender Offer”); and (ii) the voluntary discontinuity of the BDRs program of the Company (“Discontinuity of the BDR Program” and, together with the Tag Along Tender Offer, the “Tender Offer”), informs its shareholders and the market in general that the procedure for the squeeze out of the remaining BDRs of the Company, as provided in Section 2.6 of the Tender Offer Notice (“Squeeze-Out”), shall take place at B3 S.A. – Brasil, Bolsa, Balcão (the “B3”) on September 3, 2020.  The Offeror will pay the amount of BRL10.40 per BDR, which will no longer be traded at B3 from August 28, 2020 (inclusive) onwards.

The Company will keep its shareholders and the market informed on the developments of the events mentioned in this material fact, in compliance with applicable regulation.

Montevideo, August 25, 2020


Claudio Coracini

Legal Representative in Brasil

Updated on 08/26/2020 at 12:30 am